Pimavanserin
As of the edition of 20 October 2026, Pimavanserin is a small molecule: marketed, first approved in 2016 (US); acts on HTR2A; US protection ends in 2030.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Nuplazid
- First approved
- 29 April 2016 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Acadia Pharmaceuticals
- Registered trials
- 41, 8 stopped early
- Disease areas
- Nervous system; Mental health; Eye; Heart and blood vessels; Inherited and neonatal
US protection
US protection ends in 2030.
The last listed US drug-substance patent ends in 2030. The application that gives this date is held by Acadia Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product12 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 12 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Pimavanserin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HTR2A | 5-hydroxytryptamine receptor 2A | P28223 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 1 | 0 |
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 17 | 10 | 4 | 3 |
| Phase 3 | 15 | 12 | 0 | 3 |
| Phase 4 | 4 | 2 | 1 | 1 |
| All trials | 41 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Acadia Pharmaceuticals | Originator and Lead sponsor of trials | 2016 to now |